A Phase II Study of Dasatinib in the Treatment of Relapsed or Plateau Phase Multiple Myeloma
Status:
Completed
Trial end date:
2008-01-01
Target enrollment:
Participant gender:
Summary
To evaluate the response rate (Complete Response [CR] and Partial Response [PR]) to dasatinib
in patients with relapsed, refractory or plateau phase multiple myeloma whose serum
paraprotein levels are >0.5g/dL or urine paraprotein levels are >1.0g/24 hours.